103 results about "Streptococcus mastitidis" patented technology

The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and / or diagnostics. The proteins are also targets for antibiotics.

The invention provides a triple real-time fluorescent PCR method and a kit for detecting three streptococci at the same time. The kit comprises: a streptococcus agalactiae detection primer pair which is represented as the Seq ID No.1 and the Seq IN No.2 in the sequence table, a probe which is represented as the Seq ID No.3 in the sequence table, a streptococcus dysgalactiae detection primer pair which is represented as the Seq ID No.4 and the Seq ID No.5 in the sequence table, a probe which is represented as the Seq ID No.6 in the sequence table, a streptococcus iniae detection primer pair which is represented as the Seq ID No7 and the Seq ID No.8 in the sequence table, a probe which is represented as the Seq ID No.9 in the sequence table, three positive comparison sample which are represented as the Seq ID No.16, the Seq ID No.17 and the Seq ID No.18 in the sequence table, a negative comparison sample (ddH2O), a PCR buffering liquid required in fluorescent real-time quantification PCR amplification, dNTP and TaqDNAPolymerase. The method is simple and quick and is good in specificity.

The invention discloses a preparation method and application of a tilapia mossambica-derived streptococcus agalactiae recombinant CBP protein vaccine. The recombinant CBP protein vaccine is prepared from tilapia mossambica-derived streptococcus agalactiae recombinant CBP protein. The amino acid sequence of the tilapia mossambica-derived streptococcus agalactiae recombinant CBP protein is shown as a sequence 2. Tilapia mossambica-derived streptococcus agalactiae is used as a research object and is cloned into a Cbp gene from a tilapia mossambica-derived streptococcus agalactiae genome; the tilapia mossambica-derived streptococcus agalactiae is connected with a pET28a(+) carrier to construct an expression vector, and prokaryotic expression and purification are carried out in E.coliBL21(DE3), so as to obtain the recombinant CBP protein vaccine with high specificity and immune protective efficacy of 56.35 percent+ / -8.09 percent; a foundation is laid for immune prevention and treatment of tilapia mossambica streptococcus agalactiae diseases.

The invention discloses a preparation method of a pleuromutilin compound, a polymorphism and a preparation method of the polymorphism. The pleuromutilin compound comprises a 14-O-[(4-amino-6-hydroxy-pyrimidine-2-yl) thio acetyl] matrix shown in a structural formula (i) and / or a 14-O-[(4-amino-6-one-pyrimidine-2-yl) thio acetyl] matrix shown in a structural formula (ii). The novel pleuromutilin compound disclosed by the invention has obvious inhibiting effects on multiple drug resistant bacteria such as methicillin resistant staphylococcus aureus and staphylococcus epidermidis as well as common pathogenic bacteria such as escherichia coli and streptococcus mastitidis in veterinary clinics, so that the pleuromutilin compound can be applied to preparation of antibacterial drugs and particularly anti-drug resistant bacterium drugs.

The invention discloses a tilapia mossambica streptococcus agalactiae oral attenuated freeze-dried vaccine and its preparation method. According to the invention, tilapia mossambica streptococcus agalactiae attenuated bacterial strain YM001 is performed with steps of enlarge cultivation, thalline collection and freeze-drying preparation to obtain the oral attenuated vaccine. The immunizing dose, immunization program and a vaccine usage method of the vaccine can be determined through tests. The immune efficacy, security and maneuverability of the vaccine can be detected and confirmed through field tests, the result shows that the vaccine has the advantages of high protection effectiveness, good security, convenient usage and low cost, the vaccine can be used for preventing tilapia mossambica streptococcus agalactiae, and has high business value.

The invention belongs to the technical field of biology and specifically discloses the application of galectin-8 derived from Siniperca chuatsi in preparation of a bacteriostatic agent. The amino acidsequence of the galectin-8 is shown as SEQ ID NO. 1. It is found that the Siniperca chuatsi galectin-8 (ScGal8) has important antibacterial activity on typical aquatic animal pathogens; and an antibacterial experiment shows that the galectin-8 has no antibacterial activity on Aeromonas salmonicida (A. Salmonicida) and Edwardsiella tarda (E. Tarda), but has a relatively obvious inhibition effect on Streptococcus agalactiae (S. agalactiae) and Flavobacterium cloumnare (F. cloumnare), so the fish galectin-8 (rScGal8) has good application prospects in the treatment of gill rot diseases of aquaticanimals caused by Flavobacterium cloumnare.

The invention relates to a primer combination capable of detecting three kinds of streptococcus simultaneously. The primer combination consists of upstream and downstream primers capable of detectingstreptococcus agalactiae, as shown in SEQ ID MO:1, 2, upstream and downstream primers capable of detecting streptococcus dysgalactiae, as shown in SEQ ID MO:3, 4, and upstsream and downstream primerscapable of detecting streptococcus iniae, as shown in SEQ ID MO:5, 6. A reagent kit consists of a DNA extraction reagent and a PCR reaction reagent, wherein the DNA extraction reagent consists of a TEbuffer solution, proteinase k, chloroform, isopropyl alcohol, ethanol and redistilled water, and the PCR reaction reagent contains a reaction buffer solution, dNTPs, DNA polymerase, the 6 primers anddeionized water. A method for detecting the three kinds of streptococcus simultaneously comprises the steps of extracting DNA in samples through the extraction reagent, performing PCR amplification on the DNA through the reaction reagent, and performing gel electrophoresis on amplification products. The three kinds of streptococcus can be detected simultaneously, detection is simple, quick, highin sensitivity and high in specificity, and the primer combination and the method can meet requirements for large-scale molecular epidemiology investigation and analysis of aquatic animals and qualitysafety detection of aquatic products.

The invention discloses a method for screening candidate bacterial strains from fish streptococcus agalactiae vaccines. The method comprises the steps: separation and breed conservation of tilapia streptococcicosis agalactiae epidemic strains, identification of the epidemic strains and the establishing of a pathogenic library, PFGE genotype analysis of epidemic strains, toxicity determination of PFGE genotype representative strains, and immunogenicity and protection domain test of the PFGE genotype representative strains so as to obtain a candidate bacterial strains combination of a tilapia streptococcicosis agalactiae immunoprophylaxis vaccine in China. The technology has the characterizes of strong pertinence, high screening efficiency, remarkable effect and the like, and the screen candidate bacterial strains combination of the tilapia streptococcosis agalactiae immunoprophylaxis vaccine in China can protect 90% of genotypes and 96.47% of epidemic strains in the pathogenic library. The technology provides a new method for screening the candidate bacterial strains from the fish streptococcus agalactiae vaccines, is suitable for screening the candidate bacterial strains from the fish streptococcus agalactiae vaccines, and has significance and using value in immune prevention and control on fish streptococcicosis.